2025 Highlights & Healthcare Policy Updates

✅HTA Framework Reform Implementation Challenges

Australia has been pursuing a major HTA Policy and Methods Review, with the Implementation Advisory Group issuing interim guidance in 2025. Reform implementation remains a priority, but progress has been gradual.

✅Cost-Effectiveness and Pricing Pressures

Pricing remains a central HTA issue:

🔹Sponsors have withdrawn applications e.g Pfizer’s abrocitinib and Eli Lilly’s lebrikizumab (Ebglyss for moderate-to-severe atopic dermatitis) due to perceived unsustainable pricing or risk-sharing requirements in HTA pricing arrangements

🔹High therapeutic value and invocative medicines recommended by the PBAC that remain unfunded on the PBS many months later, such as Heplcudex (bulevirtide) for Hepatitis D, Joenja (leniolisib) for activated phosphoinositide 3-kinase delta syndrome (APDS), and Tepezza (teprotumumab) for Thyroid Eye Disease

✅ Horizon Scanning

Medicines Australia’s submission to Treasury’s Economic Roundtable in July 2025 on key reform priorities. The overarching theme being the need to move beyond identifying innovations to building the structures, policies and processes required to deliver on 3 themes:

🔹Fit-for-purpose regulatory and reimbursement pathways for timely patient access

🔹The importance of a values framework and methods for health technology assessment

🔹System preparedness for personalised therapies

Our team actively participated in events locally and globally:

✴️ AusBiotech and Medicines Australia’s Women in Life Sciences Luncheon

✴️ AusMedtech 25 George Papadopoulos & Blaise Agresta led “Reimbursed & Ready Winning in the Australian Market” session

✴️ Sydney University Pharmacy School by Cicada Innovations. George returned to present on healthcare and market access strategy

✴️ ARCS Australia Annual Conference 2025

As well as hosting our stand, the team participated in the sessions:

🟢 Horizon Scanning and HTA: Past, Present and Future

🟢 Medicine Access: Innovation in Action to Drive Patient Access

🟢 Future Horizons: Professional Evolution

✴️ George Papadopoulos & Michael Aristides attended Medicines Australia’s Horizon Scanning, PharmAus 2025 and Neurological Alliance Australia’s National Action Plan Launch in Canberra

✴️ Medical Technology Association of Australia (MTAA) MedTech Conference 2025

✴️ ISPOR Europe 2025 – Michael Lees attended & we showcased our 12 abstracts with Skyward Analytics

You can view and download all 12 ISPOR Eurupe 2025 Abstracts HERE

News & Milestones

➡️ George Papadopoulos appointed to Oncothera Advocacy Board of Directors

➡️ Michael Lees joins our team

➡️ We marked a decade of Lucid Health Consulting! Founded by George Papadopoulos, Michael Aristides & Steve Crowley

Thanks to our team, clients and partners for your collaboration and support in 2025. Best wishes for the festive season and 2026 🎉

Partner with Lucid Health Consulting 

At Lucid Health Consulting, we have a proven track record of enabling companies and organisations to optimise the entry of their pharmaceuticals, biotech products, medical devices, and technologies into the Australian, New Zealand and Asia-Pacific markets.

Need support with market access or regulatory strategy in Australia, New Zealand or the APAC region?
Let’s connect. Lucid Health Consulting is ready to help you bring your pharmaceutical, medical device, or biotech product or technology, to market with confidence.

Contact and follow us to learn more about our Regulatory Affairs, Quality and Advocacy services.

🔹 www.lucidhealth.com.au

🔹 info@lucidhealthcon.com

🔹 Lucid Health Consulting on LinkedIn

The post Wrapping up 2025 – Lucid Health Consulting appeared first on Lucid Health Consulting | Experience Matters.

🌟 2024 Highlights

 Healthcare Policy Updates

📌 The HTA Review Report was released in May, featuring 50 recommendations to improve equity, streamline processes, and enhance access to new technologies, including:

• Equitable access for under-represented patient groups.
• Streamlined pathways for timely technology adoption.
• Enhanced real-world data for informed HTA decisions.

📌 New HTA Committee Appointments:

• PBAC Chair: Professor Robyn Ward AM from 5 May 2024.
• MSAC: Professor Jonathan Craig as the Chair of MSAC from 1 April 2024, Professor Kwun Fong as Co-Deputy Chair of MSAC from 1 April 2024 and Associate Professor Sarah Norris as Co-Deputy Chair of MSAC from 1 July 2024.

📌 Horizon Scanning Forum 2024

• Continuing with the theme of the first Horizon Scanning Forum held in 2022 four therapeutic areas where innovative new classes of medicines and treatments stand to disrupt treatment paradigms in Australia and require innovation in system planning were presented and discussed. These were:
  • • Cell and gene therapies,
    • Vaccine technology for infectious diseases,
    • Novel antimicrobials
    • Digital health

Industry Engagement – Lucid Health Consulting team

Our team actively participated in leading events locally and globally, such as:

• AusBiotech’s International Women’s Day Luncheon
• 2024PTA-C, the inaugural Pathology Technology Australia Congress
• The Medicines of Tomorrow: Horizon Scanning Forum 2024
• ISPOR Global (Atlanta) and Europe (Barcelona)
• ARCS 2024 Annual Conference, including sponsoring the inaugural CEO Breakfast as well as hosting a booth in the exhibition hall
• The HTA Roadmap – Ideal Outcomes and Reforms workshop
• ISPOR Australia Chapter, Real-World Evidence and HTA Reform Workshop
• AusBiotech 2024, the premier event for Australia’s life sciences community
• Hosted two interns from the USA as part of the nonprofit study abroad and intercultural exchange organization CIEE.

In the News

We were honoured to help our client Tryptamine Therapeutics Limited (ASX:TYP) on the registration and reimbursement strategy for their treatment, TRP-8803 (IV-infused psilocin) globally.

Insights and Research

• Our Director Steve Crowley presented at the Asia-Pacific Value-Based Contracting Webinar Series on transparency in Managed Access Programs.

• Our Director George Papadopoulos, returned to run a session on Healthcare and Market Access Strategy at the CICADA Training Program.

• Our Director George Papadopoulos joined a panel discussing reimbursement in MedTech healthcare and the need for Australia’s HTA system to evolve in response to global trends, at AusMedtech 2024.

• Our Director Michael Aristides co-authored a joint abstract on “The cost-effectiveness of axicabtagene ciloleucel versus standard of care as second-line therapy in patients with large B-cell lymphoma in Australia.”

 Looking Ahead to 2025, Upcoming Industry Events

• AusMedTech 2025: 7–8 May, ICC, Sydney. Find out more HERE
• ISPOR Global 2025: 13–16 May, Montreal, Canada. Find out more HERE
• ARCS Annual Conference: 3–5 June, ICC, Sydney. Find out more HERE
• ISPOR Europe 2025: 9–12 November, Glasgow, Scotland. Find out more HERE
• Medicines Australia: PharmAus 2025, September 2025, Canberra.

Our Online Tools, Resources and Publications

Explore our tools via our website RESOURCES page. See our 🛠️ PBS Price Calculator | MAOSS Database | easySLR | PBS Calendar (launching soon!)

Missed our 10th Annual Drugs and Devices Australia Reimbursement Update Webinar? The recorded session is available here.

We deeply appreciate your trust and collaboration throughout 2024. Here’s to another year of innovation, progress, and partnership in 2025.

The Lucid Health Consulting Team

Providing expert advice in health economics, pricing a& reimbursement, market access and regulatory affairs in Australia and the Asia-Pacific. At Lucid Health Consulting, we have a proven track record of enabling companies and organisations to optimise the entry of their pharmaceuticals, biotech products, medical devices, and technologies into the Australian market. We understand that getting your products, devices and technologies, successfully into the Australian market matters. That getting the right price for your reimbursements matters. It matters to the patients who need your life-altering products or services at a reasonable price, and it matters to keep your business thriving.

The post Lucid Health Consulting – Wrapping Up 2024 and Looking Ahead to 2025 appeared first on Lucid Health Consulting | Experience Matters.

The post Lucid Health Consulting Appointed by Tryptamine Therapeutics Ltd for product registration and reimbursement strategy in Australia. appeared first on Lucid Health Consulting | Experience Matters.

At Lucid Health Consulting we provide expert advice in health economics, pricing & reimbursement, market access and regulatory affairs in Australia and the Asia- Pacific region. With over 30 years of Market Access, Health Economics, Regulatory & Compliance, Pricing & Reimbursement and Health Technology Assessment experience, we have helped many organisations to optimise the entry of their pharmaceutical, biotech and medical devices into the Australian and Asia-Pacific markets.

Let us show you how our strategic approach and highly experienced team can help you achieve market access in Australia. Contact and connect with us today to find out more or if you have any questions.

Contact and connect with us at Lucid Health Consulting today:

• Email: info@lucidhealthcon.com
• Phone: +61 2-8964 9600
• Website: Lucid Health Consulting | Experience Matters
• Follow us on LinkedIn:  HERE

The post Lucid Health Consulting: NEWSLETTER #1 – February 2024. appeared first on Lucid Health Consulting | Experience Matters.

We are thrilled to announce a strategic partnership with Vista Health aimed at fortifying our joint commitment to delivering unparalleled health economics, HTA, pricing & reimbursement, market access and regulatory affairs advice and solutions throughout the Asia Pacific region.

This strategic partnership ensures that both companies can now offer our clients with a seamless and holistic advisory experience across key markets, embodying a sense of continuity and reliability that’s unmatched in the industry and region.

Vista Health is known for its comprehensive expertise spanning Asia Pacific and Latin America across the healthcare spectrum encompassing providers, payers’ patients, and industry and at Lucid Health Consulting we have over three decades of health economics, HTA, pricing & reimbursement, market access, and regulatory affairs experience within Australia and New Zealand.

Founder & Managing Director of Vista Health, Joe Caputo, expressed his enthusiasm, stating, “We are very excited to be partnering with Lucid Health Consulting to better serve our clients across the Asia Pacific region and beyond. Having known George and the team for many years, the decision to formalize a partnership was very straightforward. Both companies share the same core values of client centricity and excellence in service. The partnership will only benefit our clients.”

George Papadopoulos, Founder & Managing Director of Lucid Health Consulting, echoed the sentiment, affirming, “The team at Lucid Health Consulting are very excited to partner with Joe and the team at Vista Health, to further enhance the value we provide to our clients who have an Asia Pacific focus or presence.”

This strategic collaboration marks a significant milestone in the realm of health advisory services within the Asia Pacific, signifying a united commitment to elevate standards, expand capabilities and enhance outcomes for clients seeking guidance in the intricate landscape of health economics, HTA, pricing & reimbursement, market access and regulatory affairs.

To find out more about Vista Health and connect on LinkedIn https://www.linkedin.com/company/vista-health-pte-ltd/ .

If you want to find out more about the strategic partnership agreement between Lucid Health Consulting and Vista Health, please contact:

• Lucid Health Consulting email: info@lucidhealthcon.com or phone: + 61 2 8964 9600
• Vista Health email: info@vista.health or phone: +65 6993 8532

For all media enquires please contact:

• For Lucid Health Consulting, contact Marketing Manager, Kim MacDonald via phone +61 402 833 499 or email: kim@lucidhealthcon.com
• For Vista Health, contact BD & Partnerships Head, Mungo Paterson via phone +852 6653 5506 or email: mpaterson@vista.health

The post New Strategic Partnership with Vista Health in Asia Pacific Region appeared first on Lucid Health Consulting | Experience Matters.

Katy brings extensive regulatory affairs experience, backed by training in clinical pharmacy and public health in both the Australian and New Zealand markets to our team. She is known for her innovative and entrepreneurial style in the regulatory environment which embraces the capacity to take calculated risks in both regulatory strategy development and execution.  Welcome to the Lucid Health Consulting team Katy, we are delighted to have you on board.

Lucid Health Consulting is an experienced, independent TGA Sponsor for pharmaceuticals and medical devices in Australia. As an Australian registered company we can act as a third-party sponsor for companies by:

• Sponsoring companies that do not have an established legal entity in Australia
• Acts as a local primary point of contact with the TGA
• Submitting an application to add a therapeutic good on the Australian Register of Therapeutic Goods (ARTG)
• Maintaining sponsorship after registration or listing on the ARTG
• Undertaking ongoing legal responsibilities once the therapeutic good is on the ARTG and fulfilling the obligations of the Sponsor.

If you would like to find out more about how Lucid Health Consulting could help your organisation or more about our team, click here

The post Welcome Kathryn Williams Day to the Lucid Health Consulting team appeared first on Lucid Health Consulting | Experience Matters.

MAOSS is a unique market access platform, providing a one stop shop for Australian reimbursement data needs. MAOSS has been rapidly expanding over the past 18 months in response to the needs of the Australian reimbursement market and has provided data for many strategic projects.

Using the MAOSS database, organisations looking to enhance the market access and reimbursement for drugs, devices and technologies in the Australian market, have access to:

• Free Text Search for PBS Items based on generic name, trade name, or indication
• Instant historical utilization for all current PBS items, for either business analysis or financial impact analysis
• Access to Ex-Manufacturer and DPMQ/DPMA prices over time
• Visualization of when and where price cuts have occurred
• Instant comparison of current PBS restrictions to historical PBS restrictions
• Instant links to Public Summary Documents (PSDs) for all drugs, or indications
• Free Text Search of PSDs within the PDF documents
• Ability to access MBS items, AR-DRG cost, and life tables
• All from one single portal

The MAOSS database and service offering enables organisations who are seeking market access into the Australian market to “stop wasting valuable time” when gathering data required for HTA submissions, as well as:

• Save time searching PSDs
• Save time linking utilization data from Department of Human Services
• Save time sourcing information from various team members, the data is all in one spot!
• A reliable data source that is constantly updated
• Save time knowing exactly what changes are occurring to restrictions impacting your portfolio or your competitors products

MAOSS combines data from all relevant sources into one easy to access portal

Lucid Health Consulting has over 30 years’ experience in providing expert advice in health economics, pricing & reimbursement, market access and regulatory affairs in Australia. By partnering with MAOSS, Lucid Health Consulting will be able to enhance its service offering with efficiencies in the gathering and communication of data.

George Papadopoulos, Partner & Director at Lucid Health Consulting said “We at Lucid Health Consulting are very excited to partner with MAOSS.  We’ve been using the data and analytics from MAOSS over the past year and looking forward to further enhancing the value this platform brings to our clients”.

Blaise Agresta, Managing Director at MAOSS said “The collaboration between Lucid Health Consulting and MAOSS brings together the brains and the brawn essential for successful reimbursement listing and market access. The collaboration will allow the data requirements for pharmaceutical and medical device reimbursement to be better targeted, and more relevant to the end user than ever before”.

To find out more about the strategic partnership agreement between Lucid Health Consulting and MAOSS contact:

• Lucid Health Consulting email: info@lucidhealthcon.com or phone: + 61 2 8964 9600
• MAOSS email: info@maoss.com.au or phone: +61 413 759 970
• Media enquiries: Kim MacDonald, Spindrift Marketing, phone +61 402 833 499

The post Lucid Health Consulting enters strategic agreement with MAOSS – for Australian Market Access Data appeared first on Lucid Health Consulting | Experience Matters.